Singapore markets closed
  • Straits Times Index

    3,153.14
    -4.83 (-0.15%)
     
  • S&P 500

    4,238.75
    -8.69 (-0.20%)
     
  • Dow

    34,349.15
    -130.45 (-0.38%)
     
  • Nasdaq

    14,078.87
    +9.45 (+0.07%)
     
  • BTC-USD

    40,852.05
    +5,015.02 (+13.99%)
     
  • CMC Crypto 200

    1,014.24
    +45.40 (+4.69%)
     
  • FTSE 100

    7,160.91
    +26.85 (+0.38%)
     
  • Gold

    1,869.20
    -10.40 (-0.55%)
     
  • Crude Oil

    71.65
    +0.74 (+1.04%)
     
  • 10-Yr Bond

    1.4860
    +0.0240 (+1.64%)
     
  • Nikkei

    29,161.80
    +213.07 (+0.74%)
     
  • Hang Seng

    28,842.13
    +103.23 (+0.36%)
     
  • FTSE Bursa Malaysia

    1,582.46
    +7.30 (+0.46%)
     
  • Jakarta Composite Index

    6,080.38
    -15.11 (-0.25%)
     
  • PSE Index

    6,917.49
    +9.70 (+0.14%)
     

Marinus Pharmaceuticals Reschedules First Quarter 2021 Financial Results Conference Call

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.

New Date and Time: Monday, May 17 at 8:30 AM Eastern

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that it has rescheduled its Fiscal First Quarter 2021 financial results conference call, originally scheduled for Thursday May 13, 2021 at 4:30 PM Eastern. The call will now be held on Monday, May 17 at 8:30 AM ET.

Access to the call remains the same as originally planned:

Domestic: (833) 979-2765
International: (343) 761-2590
Webcast Link: https://event.on24.com/wcc/r/3081130/88D98EC340CEF9104A24FACA2A4283B7
Conference ID: 6864408

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus recently completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, is conducting a Phase 2 trial in tuberous sclerosis complex and has recently disclosed top line results from its Phase 2 proof-of-concept trial in PCDH19-related epilepsy. The company has initiated a Phase 3 trial in refractory status epilepticus. For more information visit www.marinuspharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005741/en/

Contacts

Sasha Damouni Ellis
Vice President, Investor Relations & Corporate Communications
Marinus Pharmaceuticals, Inc.
484-253-6792
sdamouni@marinuspharma.com